PLUS THERAPEUTICS, INC. (PSTV)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Revenue | 1,390 | 1,456 | ||
| Research and development | 1,246 | 2,858 | ||
| General and administrative | 1,682 | 2,397 | ||
| Total operating expenses | 2,928 | 5,255 | ||
| Operating loss | -1,538 | -3,799 | ||
| Interest expense | - | 61 | ||
| Fair value loss on warrant liability | - | -960 | ||
| Warrant issuance costs | - | 54 | ||
| Interest income | 27 | 80 | ||
| Financing expenses | -150 | - | ||
| Change in fair value of derivative instruments | -6,512 | - | ||
| Total other income (expense) | 6,689 | 925 | ||
| Net income (loss) | 5,151 | -2,874 | ||
| Earnings per share basic | 0.02 | -0.37 | ||
| Earnings per share diluted | -0.01 | -0.37 | ||
| Weighted average number of diluted shares outstanding | 209,154,994 | 7,855,763 | ||
| Weighted average number of shares outstanding basic | 48,388,862 | 7,855,763 | ||